Colorectal Cancer-Heat Map and Analysis

Colorectal Cancer-Heat Map and Analysis

  • Products Id :- GBIHC0013HM
  • |
  • Pages: 21
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Colorectal Cancer-Heat Map and Analysis


Colorectal cancer (CRC), otherwise known as bowel cancer, is a malignancy originating in the colon (the large intestine) or rectum, both of which are located towards the end of the human gastrointestinal tract. It begins as a benign tumor, which is almost always in the form of a small polyp within the colon or rectum. It rarely occurs in the absence of polyps, although can arise as a result of an inflammatory bowel disease such as Crohn's disease or ulcerative colitis. CRC was the third most prolific oncological indication with regard to the number of new cases in the US in 2016.

The disease can be divided into two categories based on how advanced it is upon diagnosis. These are early-stage (adjuvant) CRC, which can be treated with surgery, and metastatic (advanced) CRC, which cannot. Therapeutic options differ between the two treatment settings, with therapies for adjuvant CRC aiming to prevent disease re-occurrence and those for advanced conditions aiming to slow disease progression while maintaining the patient's quality of life.

Targeted therapies have already begun to extend the lifespan of metastatic CRC patients compared with chemotherapy-only regimens. However, there remains an unmet need to improve the efficacy of treatment options and extend survival for these patients. Additionally, an unmet need exists for patients with KRAS mutation-positive CRC, for whom certain currently marketed therapies are not recommended.

This tabular heatmap framework, designed to provide an easily digestible summary of these clinical characteristics, provides detailed information on all late-stage clinical trial results for products in the CRC market, with additional focus on the late-stage pipeline. These are split along therapy lines, and are therefore reflective of the treatment algorithm.

All safety and efficacy endpoints reported in these trials are displayed, for both the drug and placebo groups. In addition, key study characteristics such as the size, composition and patient segment of the study population are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease of use.

The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.


How is the colorectal cancer market landscape expected to change with regard to therapeutic type, due to promising pipeline therapies?

What are the clinical characteristics of currently approved therapies for colorectal cancer, in terms of specific safety and efficacy parameters?

How are clinical safety and efficacy parameters linked to the key unmet needs in this indication?

How will current late-stage immunotherapeutics affect the colorectal cancer market, and will they be able to satisfy current unmet need with regard to effective therapy options?

Are future product approvals likely to affect the treatment algorithm significantly?

Reasons to Buy

Understand the current clinical landscape by considering the treatment options available for early- and late-stage disease.

Visually compare the currently approved treatments available at each line of therapy, based on the most important efficacy and safety parameters tested in clinical trials.

Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy.

Understand the relative strengths and weaknesses of the studies used to gather these data.

Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks.

Assess your own pipeline programs in light of these benchmarks in order to optimally position them and maximize uptake by clinicians.

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


1 Table of Contents

1 Table of Contents 2

2 Introduction 3

2.1 Report Guidance 6

3 Marketed Products 7

3.1 Early-Stage Adjuvant Therapy 7

3.2 Advanced (Unresectable or Metastatic) Therapy 8

3.2.1 Chemotherapy 9

3.2.2 Targeted Therapies 10

4 Pipeline Products 13

4.1 Changes to Early-Stage Adjuvant Therapies, 2017-2022 13

4.2 Changes to Advanced (Unresectable or Metastatic) Therapies, 2017-2022 13

4.2.1 Changes to Chemotherapies, 2017-2022 13

4.2.2 Changes to Targeted Therapies, 2017-2022 14

5 Appendix 17

5.1 Abbreviations 17

5.2 References 18

5.3 Research Methodology 21

5.4 Contact Us 21

5.5 Disclaimer 21

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

select a license
Single User License
USD 2000 INR 142780
Site License
USD 4000 INR 285560
Corporate User License
USD 6000 INR 428340



The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]